Exelixis, Inc.EXELNASDAQ
Loading
R&D Expense Growth Recovery in ProgressRecovering
Percentile Rank29
Studio
Year-over-Year Change

Year-over-year research & development expense growth

Percentile
P29
Within normal range
vs 5Y Ago
-0.1x
Contraction
Streak
1 yr
Consecutive growthRecovering
PeriodValue
2025-9.38%
2024-12.80%
202317.07%
202228.56%
202126.62%
202062.58%
201984.88%
201862.48%
201716.88%
2016-0.40%